Key result
Endo-TLIF with rhBMP-2 achieves similar fusion to MIS-TLIF while reducing blood loss and hospital stay.
Why the study?
Several minimally invasive techniques for lumbar spine interbody fusion minimize surgical morbidity, but the efficacy of endoscopic TLIF compared with minimally invasive TLIF in 1-segment lumbar spondylolisthesis required evaluation.
Does Endo-TLIF improve perioperative characteristics and clinical outcomes compared to MIS-TLIF in patients with 1-segment lumbar spondylolisthesis?
RCT (n=102)
single-blind
single-blind quasi-randomization
No
Does Endo-TLIF improve perioperative characteristics and clinical outcomes compared to MIS-TLIF in patients with 1-segment lumbar spondylolisthesis?
Endo-TLIF is a feasible and effective alternative to MIS-TLIF for 1-segment lumbar spondylolisthesis, offering less muscle damage and faster recovery despite longer operative times.
Answers are grounded in this paper and cite their sources.
Supports Endo-TLIF as alternative to MIS-TLIF with perioperative advantages; extends RCT data on endoscopic fusion for spondylolisthesis.
BackgroundThere are currently several minimally invasive techniques for lumbar spine interbody fusion that have been shown to minimize surgical and perioperative morbidity. We aimed to evaluate the curative efficacy of endoscopic transforaminal lumbar interbody fusion (Endo-TLIF) by comparing perioperative characteristics and 1.5-year observational outcomes in 1-segment lumbar spondylolisthesis between the minimally invasive TLIF (MIS-TLIF) technique and the optimized Endo-TLIF technique. MethodsOne hundred and two patients treated by MIS-TLIF (48 cases) or Endo-TLIF (54 cases) were included from January 2017 to January 2019. Perioperative parameters and clinical outcomes were evaluated. Inflammatory biomarkers were measured for postoperative traumatic stress and muscle injury. Fusion rates were determined at 18 months after surgery by CT and the necessity of recombinant human bone morphogenetic protein-2 (rhBMP-2) application in Endo-TLIF was also observed. ResultsThe Endo-TLIF group had similar incision length, return to work time and rate (p>0.05). Blood loss, left bed time and analgesic ratio were significantly less in Endo-TLIF group (p<0.05). The Endo-TLIF group had a significantly longer operative and radiation exposure time compared with MIS-TLIF group (p<0.05). The CRP and ESR levels were lower in the Endo-TLIF group compared with the MIS-TLIF group (p<0.05). The VAS and ODI improved significantly in both groups after surgery. Significant decreases in low back VAS in the Endo-TLIF group were found at postoperative day 1 and 3 months after surgery (p<0.05). The fusion rate in the Endo-TLIF/rhBMP-2 group (75%) was lower than that in the MIS-TLIF group (95.8%),but it was similar to that in the Endo-TLIF/rhBMP-2 group (90%).ConclusionsEndo-TLIF has comparable perioperative analysis and clinical outcomes in comparison to MIS-TLIF and manifests a greater improvement in less multifidus muscle damage, inflammation and faster patient recovery. Thus, Endo-TLIF should be considered as a feasible and effective technique for 1-segment lumbar spondylolisthesis patients.Trial registration: ChiCTR1800015197, 13 March 2018. Trial registry: Chinese Clinical Trial Registry.
No takes yet. Share an insight, caveat, or question.
Lv et al. (2021) conducted an RCT in 1-segment lumbar spondylolisthesis (n=102). Endoscopic transforaminal lumbar interbody fusion (Endo-TLIF) vs. Minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) was evaluated on Fusion rate at 18 months (Endo-TLIF with rhBMP-2 vs MIS-TLIF) (p=0.306). Endo-TLIF with rhBMP-2 achieved a similar 18-month fusion rate compared to MIS-TLIF for 1-segment lumbar spondylolisthesis, while reducing blood loss and hospital stay.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: